SEOUL, South Korea, March 15, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading global provider of AI-powered cancer solutions, today announced its participation in the American Association for Cancer Research (AACR) Annual Meeting 2023. Lunit will deliver five poster presentations featuring its AI-biomarker platform at the annual meeting to be held in Orlando, Florida, on April 14-19.
As a leading provider of state-of-the-art cancer diagnostic technology, Lunit has focused on developing novel AI biomarkers for application in immunotherapy. Since 2019, the company has released groundbreaking findings based on its AI-powered tissue analysis platform, Lunit SCOPE, at the AACR's annual meetings. This year's presentations will feature the newest studies demonstrating the predictive value of Lunit's AI biomarker platform, Lunit SCOPE IO—part of the Lunit SCOPE suite.
Lunit's presentations at AACR 2023 are as follows:
"This year, we are excited to bring new research using Lunit SCOPE in more cancer types and treatment settings," said Brandon Suh, CEO of Lunit. "Lunit will continue to enable novel academic research and innovative product development to provide the most appropriate treatment for cancer patients."
Visit the Lunit team at Booth 2671. Reach out to schedule a meeting at (email@example.com).